Acerola whole fruit concentrate

Identity and Botanical Source

"Acerola whole fruit concentrate" is a food-derived ingredient manufactured from the fruit of the acerola tree, a small tropical shrub classified botanically as Malpighia emarginata DC. (synonymous in older literature with Malpighia glabra and Malpighia punicifolia), family Malpighiaceae. The fruits of Malpighia glabra and M. emarginata are commonly known as "Acerola cherry" or "Barbados cherry." Acerola is a tropical, fruit-bearing, evergreen shrub belonging to the family Malpighiaceae in the order Malpighiales, also known as Barbados cherry and West Indian cherry, native to Central and South America and the Caribbean Islands. It is cultivated in tropical and subtropical countries, especially in northwestern Brazil and the Mekong Delta region of Vietnam (Tien Giang Province and Ben Tre Province), primarily to meet the demand of the fresh fruit market and/or processing industries.

"Whole fruit concentrate" refers to a processed preparation in which the entire edible pulp (and sometimes peel) of the fresh fruit is pressed, filtered, and concentrated — typically by water-based extraction, evaporation, and/or spray-drying — without isolating or purifying a single compound such as ascorbic acid. This is produced by optimized extraction of ascorbic acid from whole green acerola fruits using response surface methodology, with solvent composition and temperature as independent variables, and evaluation using cellular antioxidant models. Spray drying with arabic gum as a carrier can produce a stable powder with low water activity, with no significant loss of antioxidant composition or activity. Because the whole fruit matrix is retained, these concentrates contain not only ascorbic acid but the full complement of co-occurring phenolics, carotenoids, and minerals naturally present in the pulp, distinguishing them from isolated or purified ascorbic acid.

Because acerola fruits are rich in vitamin C (ascorbic acid), their concentrated juice is used as a raw material for preparing beverages and supplemental vitamin C powder. Acerola fruit contains 20 to 30 times more vitamin C than orange, making it one of the fruits richest in vitamin C (1000 mg to 2000 mg per 100 g), after Terminalia ferdinandiana and camu-camu (Myrciaria dubia). Unripe or "green" acerola fruit is particularly concentrated in ascorbic acid: among tropical fruits, acerola stands out for its exceptionally high vitamin C content, exceeding 4,000 mg per 100 g of fresh fruit, with strong antioxidant activity.

Traditional and Historical Use

Documented traditional use of acerola is comparatively sparse relative to its modern commercial prominence. Acerola is believed to originate from the Yucatan, and traditionally the fruits have been used to treat dysentery, diarrhea, and liver disorders, with other ethnobotanical uses as an astringent and for fever. Also present in the Amazon rainforest, it was traditionally used by Indigenous peoples to treat diarrhea, sore throat, and liver disorders. In Brazil, where the fruit is now most extensively cultivated and consumed, folk use has extended to a broader range of complaints, reported as nutritional support for conditions such as anemia, high cholesterol, diabetes, liver conditions, rheumatism, and tuberculosis, alongside its use for diarrhea, dysentery, and wound healing.

Acerola's rise to scientific and commercial prominence is a mid-20th-century phenomenon rather than an ancient one. It was essentially unknown to Western science until systematic investigation in the 1940s; subsequent agricultural and nutritional research in Puerto Rico and Brazil established its exceptional ascorbic acid content, after which cultivation expanded for both fresh fruit and industrial vitamin C production. This contrasts with better-documented tropical ethnomedicines (such as soursop or guanabana) for which colonial-era and pre-colonial written ethnobotanical records are more extensive; for acerola specifically, much of what is described as "traditional" use reflects regional folk medicine practices recorded primarily in 20th-century ethnobotanical surveys of Brazil, Venezuela, and the Caribbean rather than pre-Columbian textual sources.

Phytochemistry: Key Constituents and Mechanisms

The dominant and best-characterized constituent of acerola whole fruit concentrate is L-ascorbic acid (vitamin C), present together with its oxidized form dehydroascorbic acid. Acerola contains vitamin C 1% to 4.5% (1,000 to 4,500 mg per 100 g) as ascorbic and dehydroascorbic acids in the edible portion of the fruit, an amount 50 to 100 times that of ascorbic acid found in an orange or lemon. It is principally known for its high vitamin C content, varying between 3 and 46 g/kg of pulp, being one of the most important natural sources for this vitamin, with consumption of three fruit units per day satisfying the vitamin C recommended dietary allowance for an adult. Total ascorbic acid content has been measured at 6.32 to 9.20 g/kg of pulp and 9.44–17.97 g/L of juice, values sensibly higher than those found in other fruit juices such as orange juice (0.516 g/L), grapefruit juice (0.274 g/L), or lemon juice (0.327 g/L).

Beyond ascorbic acid, whole fruit concentrates retain a range of secondary metabolites. Besides vitamin C, acerola fruits may be also a good source of phytochemicals such as anthocyanins, flavonoids and phenolic acids, and polyphenols. Although the anthocyanin content measured in acerola is 2.7 to 7.8 mg/100 g fresh weight — much lower than that of berry fruits — the total phenolic content is about three times as high, around 3,300 to 4,400 mg/100 g fresh weight. Acerola pulp also contains significant amounts of phenolic compounds, with about 452 to 751 mg gallic acid equivalent (GAE) per 100 g in frozen pulps. Phytochemical profiling of the pulp has identified flavonoids such as quercitrin and aceronidin alongside its high vitamin C content. Carotenoids and B-complex vitamins (thiamine, riboflavin, niacin) are also reported constituents of the fruit's nutrient profile.

Mechanistically, ascorbic acid is a water-soluble reducing agent and essential cofactor for enzymes including prolyl and lysyl hydroxylases involved in collagen synthesis, and it participates in cellular redox homeostasis as a direct free-radical scavenger and a regenerator of other antioxidants such as vitamin E. Key compounds in acerola, including ascorbic acid, hydroxycinnamic acids, flavonoids, and polysaccharides, are associated with the modulation of redox homeostasis, inflammatory signaling, and lipid metabolism, particularly under high-fat dietary conditions. In cell-based assays, green acerola extracts significantly preserved cell viability under menadione-induced oxidative stress, with the high ascorbic acid content of the optimized aqueous extract (63.98% of dry matter) identified as the primary candidate responsible for the antioxidant protection observed.

There is also preliminary evidence that the whole-fruit polyphenol matrix may influence intestinal vitamin C handling rather than ascorbic acid acting in isolation. An in vitro study noted increased expression of sodium-dependent vitamin C transporter 1 in intestinal cells caused by other polyphenols present in acerola juice, with the authors concluding that acerola may be better absorbed by humans than synthetic ascorbic acid. Compounds outside the fruit pulp have also been characterized: three norfriedelins with acetylcholinesterase-inhibitory activity were previously found in the acerola tree, and further examination of the lipophilic constituents of the plant's aerial parts yielded three new tetranorditerpenes with a rare 2H-benz[e]inden-2-one substructure — findings that illustrate the chemical complexity of the acerola plant overall, though these particular compounds derive from leaves/stems rather than the fruit concentrate itself.

Scientific Evidence by Area of Use

Vitamin C Bioavailability and the "Whole Food Matrix" Question

The most direct, acerola-specific human data concern whether vitamin C delivered within the whole fruit matrix behaves differently in the body than isolated ascorbic acid. In a bioavailability and pharmacokinetic study conducted in young healthy Japanese males, the net 6-hour urinary excretion of ascorbic acid was lower after ingestion of acerola juice than after ingestion of commercial ascorbic acid alone, suggesting acerola may be better absorbed by humans than synthetic ascorbic acid. A more recent narrative synthesis of this literature found: earlier pharmacokinetic evidence demonstrated that ingestion of acerola juice containing 50 mg of ascorbic acid resulted in greater plasma exposure and lower urinary excretion compared with isolated ascorbic acid, supporting a matrix-dependent modulation of vitamin C handling. However, the same review is explicit about the limits of this evidence: human evidence remains limited but suggests matrix-dependent effects on vitamin C bioavailability and selected cardiometabolic markers. A professional clinical monograph reaches a similarly cautious conclusion, noting that acerola has been investigated primarily in vitro and in animal studies for potential antioxidant, antifungal/antimicrobial, hypoglycemic, hepatic, dermatologic, and CNS effects, but clinical trial data are lacking to recommend use for any indication. Superiority over a standard multivitamin preparation also remains unclear.

This is reinforced by a broader (non-acerola-specific) randomized crossover trial comparing vitamin C bioavailability from supplements, whole produce, and juice: in twelve healthy adults given equivalent 101.7 mg doses of vitamin C via powder, raw fruits/vegetables, or juice in a crossover design, all interventions elevated plasma vitamin C levels, with juice yielding the highest area-under-curve exposure. Earlier reviews of vitamin C bioavailability research have been more skeptical of "natural vs. synthetic" claims generally: the possibility that bioavailability of L-ascorbic acid from natural sources might differ from synthetic ascorbic acid was investigated in at least two human studies, and no clinically significant differences were observed. Taken together, the evidence for a meaningful, clinically important absorption advantage of acerola-derived vitamin C over synthetic ascorbic acid is preliminary, based on a small number of pharmacokinetic studies with limited sample sizes, and is not yet considered definitively established.

Immune Function and the Common Cold

No cold/infection trials specific to acerola whole fruit concentrate were identified; the relevant evidence pertains to vitamin C generally, which is the dominant active constituent of acerola concentrates. A Cochrane systematic review restricted to placebo-controlled trials testing 0.2 g/day or more of vitamin C found that regular ingestion of vitamin C had no effect on common cold incidence in the ordinary population, based on 29 trial comparisons involving over 11,000 participants. In adults, duration of colds was reduced by 8% and in children by 14%, with 1 to 2 g/day shortening colds by 18% in children; cold severity was also reduced by regular supplementation. However, seven comparisons examining therapeutic vitamin C (started after cold onset) showed no consistent effect on duration or severity. The review's authors concluded: the failure of vitamin C supplementation to reduce the incidence of colds in the general population indicates that routine vitamin C supplementation is not justified, yet vitamin C may be useful for people exposed to brief periods of severe physical exercise. This body of evidence is strong methodologically (Cochrane meta-analysis of randomized trials) but applies to vitamin C as a nutrient broadly, not to acerola whole fruit concentrate as a tested intervention; no inference about whole-fruit-specific immune benefits beyond its vitamin C content can be drawn from it.

Skin Health and Photoprotection

Human evidence in this domain comes exclusively from multi-ingredient oral collagen products that include acerola fruit extract as one component alongside hydrolyzed collagen peptides, vitamin C, zinc, biotin, and vitamin E — not from acerola concentrate tested alone. In a randomized, placebo-controlled, blind study, 72 healthy women aged 35 or older received a drinking-ampoule blend of 2.5 g collagen peptides, 666 mg acerola fruit extract, 80 mg vitamin C, 3 mg zinc, 2.3 mg vitamin E, and 50 µg biotin, or placebo, for twelve weeks. The test product significantly improved skin hydration, elasticity, roughness, and density as assessed by corneometry, cutometry, 3D phase-shift imaging, and sonography. A related triple-blind trial using the same formulation reported that objective, blinded, validated image analyses using confocal laser scanning microscopy showed a significant improvement of facial skin collagen structure after intake of the test product, while no improvements were found after placebo. A separate trial combining hydrolyzed fish collagen with goji berry, aloe vera, chamomile, and acerola cherry in 60 subjects found the combination significantly increased skin collagen content (6.1% vs. 3.3%, p<0.001), elasticity (8.2% vs. 3.8%), and reduced UV spots (-4.4% vs. 1.0%) compared to placebo. Because acerola was one ingredient among several active compounds in each of these trials, the isolated contribution of acerola whole fruit concentrate to the observed skin outcomes cannot be determined from this evidence; it should be regarded as supportive but not independently confirmatory of an acerola-specific skin benefit.

Preclinical (animal) work provides mechanistic plausibility for a photoprotective role specific to acerola's whole-fruit matrix. In a hairless-mouse model lacking endogenous vitamin C synthesis, five-week-old hairless mice were given drinking water containing physiologically sufficient ascorbic acid, no ascorbic acid, or 1.67% acerola juice, then exposed to UVB irradiation three times weekly for six weeks. Acerola juice intake suppressed the UVB-induced decrease in skin lightness (L* value) seen in the ascorbic-acid-sufficient group, and was associated with a significant decrease in expression of dopachrome tautomerase, an enzyme involved in melanin biosynthesis. The authors concluded that acerola juice intake is effective in suppressing UVB-induced skin pigmentation by inhibiting melanogenesis-related genes. This remains an animal-model finding and has not been confirmed in human photoprotection trials of acerola alone.

Metabolic, Hepatic, and Cardiometabolic Parameters

Evidence here is largely preclinical, with one small human field study in athletes. In a study of elite athletes, subjects were supplemented with acerola pulp at a dose of 300 g/day in three daily doses for three weeks, with laboratory analyses performed before and after supplementation. Three-week exposure to acerola led to significant improvements in metabolic markers including glucose (4.8 vs. 4.6 mmol/L, p = 0.001). The authors also noted that hypoglycemic and hypocholesterolemic effects had been reported in experimental in vitro and animal studies, but stated that clinical evidence from human studies is otherwise lacking. This athlete study used an unblinded, uncontrolled before/after design in a small, specific population, which substantially limits generalizability.

Animal data on metabolic and hepatic outcomes are more extensive. In diet-induced obesity models, acerola-derived polysaccharides given orally at 200–800 mg/kg for nine weeks in high-fat-diet mice reduced hepatic lipid accumulation and markers of lipogenesis (SREBP-1c, FAS, ACC, SCD-1), while increasing mitochondrial complex activity and PGC-1α expression. Freeze-dried acerola by-products (peels, residual pulp, and seeds) administered orogastrically at 400 mg/kg for 28 days to Wistar rats on a high-fat diet reduced liver fat accumulation, serum lipids, and blood glucose while increasing insulin tolerance and fecal bile acid excretion in models of both metabolic dysfunction and diet-induced dyslipidemia. These findings, while mechanistically coherent with acerola's phenolic and polysaccharide content, remain confined to rodent models and have not yet been replicated in controlled human trials.

A 2025–2026 narrative review summarizing both the animal and human literature concluded cautiously that human evidence remains limited but suggests matrix-dependent effects on vitamin C bioavailability and selected cardiometabolic markers — language indicating that cardiometabolic claims for acerola in humans are, at present, hypothesis-generating rather than established.

Antioxidant, Hepatoprotective, and Antimicrobial Effects (Preclinical)

Antioxidant activity is the most consistently demonstrated property of acerola across in vitro and cell-based assays. With respect to bioactivities, acerola showed antioxidant, antimicrobial, hepatoprotective, and anti-hyperglycemic effects in laboratory studies. Acerola is renowned for its numerous reported health benefits, including antihyperglycemic effect, hepatoprotective effect, skin lightening, and potential in preventing hyperglycemia and dyslipidemia in diabetic individuals. These claims are drawn chiefly from cell culture and animal experiments; as with the metabolic effects described above, they have not been confirmed by controlled clinical trials in humans and should be regarded as preliminary.

Body Systems and Health Areas Associated with Acerola

• Immune system — via its vitamin C content, relevant to general immune cell function; population-level cold-prevention benefit is not supported by meta-analysis, though modest reductions in cold duration/severity with regular (not therapeutic) supplementation have been reported for vitamin C generally.
• Integumentary system (skin) — collagen synthesis support (established vitamin C cofactor mechanism) and photoprotection/pigmentation modulation (demonstrated in animal models; supportive but not acerola-isolated human evidence from combination collagen-supplement trials).
• Hepatic and metabolic systems — hepatoprotective and lipid/glucose-modulating effects demonstrated in rodent models of diet-induced liver fat accumulation and dyslipidemia; limited human data from a small, uncontrolled athlete study.
• Antioxidant/cellular redox status — demonstrated in vitro via free-radical scavenging (DPPH, ABTS) and cellular antioxidant protection assays.
• Gastrointestinal system — historical/traditional use for diarrhea and dysentery; not evaluated in modern controlled trials.

Dosage Forms and Reported Dosages

Acerola whole fruit concentrate is marketed in several forms, reflecting both food and supplement uses: food use includes juices, purees, frozen pulp, and culinary powders added to smoothies, while supplement use comprises standardized powders, tablets, and capsules designed to deliver a specific vitamin C dose. Commercial extracts are typically standardized to a declared percentage of natural vitamin C (commonly in the range of roughly 17% to 32% by weight in industry specification sheets), with the remainder of the material consisting of the retained fruit matrix (fiber, sugars, minerals, and polyphenols).

Reported dosage figures vary considerably across sources because no official regulatory dosage has been established:

• To date, official agencies have not issued any dosage recommendations for tablets, capsules, juices, or powders made from acerola cherries.
• A professional nutrition reference states that typical supplemental dosages range from 40 to 100 milligrams daily, although specific therapeutic doses have not been clinically established by clinical studies.
• In the human pharmacokinetic study discussed above, acerola juice containing 50 mg of ascorbic acid was the tested dose.
• In the athlete field study, acerola pulp was dosed at 300 g/day, divided into three daily doses, for three weeks.
• In the skin-health collagen trials, the acerola-containing formulations supplied 666 mg of acerola fruit extract per daily serving alongside the collagen peptides and other actives, taken daily for 12 weeks.

Because acerola whole fruit concentrate is a food-matrix ingredient rather than a single standardized molecule, product labels generally express dosage either as milligrams of the fruit concentrate/extract itself or as the milligrams of vitamin C it supplies — these two figures are not interchangeable and depend entirely on the standardization of the specific product.

Safety Considerations and Interactions

Acerola whole fruit concentrate's safety profile is governed largely by its principal constituent, vitamin C, since typical consumption delivers ascorbic acid in substantial amounts relative to isolated-vitamin products of the same weight.

Gastrointestinal effects: Excessive intake can lead to side effects such as gastrointestinal discomfort.

Possible latex cross-reactivity: Individuals allergic to latex may also react to acerola.

Kidney stone risk at high doses: Because ascorbic acid is partly metabolized to oxalate, high-dose vitamin C intake (as could be delivered by concentrated acerola products taken in large quantities) has been studied for its effect on urinary oxalate. In a controlled study, adult calcium-oxalate stone-formers given 1 gram or 2 grams of vitamin C daily for three days, and healthy non-stone-forming adults given 1 gram daily, showed no change in urinary pH, but statistically significant increases in oxalate excretion occurred in all three groups (61% in the 1 g group, 41% in the 2 g group, and 56% in healthy controls), along with a significant increase in calcium oxalate urinary supersaturation. A related large epidemiological study, however, found a more selective pattern: no positive association between consumption of vitamin C supplements and the risk of kidney stones was observed in women in that cohort, suggesting the clinical stone-forming risk from high-dose vitamin C may be more relevant in men and in individuals who are already calcium-oxalate stone formers than in the general population.

Dose-dependence of effects: The underlying vitamin C evidence base indicates that benefits (e.g., modestly reduced cold duration/severity) and risks (e.g., oxalate elevation) both appear to be dose-related phenomena tied to total ascorbic acid intake, meaning the practical safety profile of an acerola concentrate product depends heavily on how much vitamin C it is standardized to deliver per serving, not on the "acerola" label alone.

Lack of established therapeutic dosing: Clinical reference sources are explicit that no clinically validated therapeutic dose of acerola exists for any indication: clinical trial data are lacking to recommend use for any indication, despite extensive preclinical investigation of its antioxidant, antimicrobial, hypoglycemic, hepatic, dermatologic, and CNS effects.

References

• Malpighia emarginata - an overview (ScienceDirect Topics)
• Green Acerola (Malpighia emarginata) Extraction Optimization, Cellular Antioxidant Activity, and Spray Drying: Toward a Stable Vitamin C-Rich Powder
• Green Acerola (Malpighia emarginata) Extraction Optimization, Cellular Antioxidant Activity, and Spray Drying: Toward a Stable Vitamin C-Rich Powder - PMC
• Health benefits of acerola (Malpighia spp) and its by-products: A comprehensive review - ScienceDirect
• Three New Tetranorditerpenes from Aerial Parts of Acerola Cherry (Malpighia emarginata)
• Chromosome-scale genome assembly of acerola (Malpighia emarginata DC.)
• Antioxidant compounds and antioxidant activity in acerola (Malpighia emarginata DC.) fruits and derivatives - ScienceDirect
• Encapsulation of W/O/W Acerola Emulsion by Spray Drying: Optimization, Release Kinetics, and Storage Stability - PMC
• Acerola Uses, Benefits & Side Effects - Drugs.com
• Acerola Uses, Benefits & Dosage - Drugs.com Clinical Overview
• Acerola and Its By-Products as Sources of Bioactive Compounds: Phytochemical Profile and Biological Effects in Experimental and Clinical Studies - PMC
• Comparative Bioavailability of Vitamin C After Short-Term Consumption of Raw Fruits and Vegetables and Their Juices: A Randomized Crossover Study - PMC
• Supplemental Forms - Linus Pauling Institute
• The Effect of Acerola Intake on Metabolic and Immunological Parameters in Elite Athletes - PMC
• A Collagen Supplement Improves Skin Hydration, Elasticity, Roughness, and Density: Results of a Randomized, Placebo-Controlled, Blind Study - PMC
• A Dermonutrient Containing Special Collagen Peptides Improves Skin Structure and Function - PMC
• Anti-Aging Effects of Hydrolyzed Collagen Beverage with Herbal Extracts on Facial Skin
• Acerola Juice Intake Suppresses UVB-Induced Skin Pigmentation in SMP30/GNL Knockout Hairless Mice - PMC
• Acerola Juice Intake Suppresses UVB-Induced Skin Pigmentation in SMP30/GNL Knockout Hairless Mice - PLOS ONE
• Vitamin C for preventing and treating the common cold - Cochrane Database of Systematic Reviews
• Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients - Kidney International
• Vitamin C Supplementation and Urinary Oxalate Excretion - Reviews in Urology (PMC)
• Acerola as a dietary supplement - EBSCO Research Starters